105462-23-5

Basic information

• Product Name: [1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid)
• Synonyms: [1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid);Risedronate Related CoMpound A;Risedronate Related Compound A (20 mg) ([1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid));NE 58018;P,P'-[1-Hydroxy-2-(2-pyridinyl)ethylidene]bisphosphonic acid
• CAS NO: 105462-23-5
• Molecular Formula: C7H11NO7P2
• Molecular Weight: 283
• Mol File: 105462-23-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• BRN: 8151626
• CAS DataBase Reference: [1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid)(CAS DataBase Reference)
• NIST Chemistry Reference: [1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid)(105462-23-5)
• EPA Substance Registry System: [1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid)(105462-23-5)

Safety Data

• Hazard Codes: Xi
• Statements: 42/43
• Safety Statements: 36/37
• Hazardous Substances Data: 105462-23-5(Hazardous Substances Data)

Usage

Description

[1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid), also known as 1-Hydroxy-2-(2-pyridinyl) Risedronate, is a compound derived from the synthesis of Risedronate (R521505), a pyridinyl biphosphonate. It is characterized by its unique chemical structure, which includes a hydroxy group and a pyridinyl group connected to an ethylidene bridge, with two phosphonic acid groups attached. [1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid) is an impurity in the synthesis process of Risedronate, which is a bone resorption inhibitor.

Uses

Used in Pharmaceutical Industry:
[1-hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid) is used as an impurity in the synthesis of Risedronate for the development of bone resorption inhibitors. Its presence in the synthesis process is significant as it can impact the purity and efficacy of the final product, Risedronate, which is a crucial medication for treating conditions related to bone resorption, such as osteoporosis and Paget's disease of bone.
Additionally, due to its structural similarity to Risedronate, it may also be studied for potential applications in the development of new bone resorption inhibitors or other related pharmaceutical compounds. Further research and development in this area could lead to the discovery of novel therapeutic agents for bone-related disorders.

Upstream product

• 13115-43-0 2-pyridineacetic acid 

Downstream Products

• 334708-63-3 1-hydroxy-2-(2-pyridinyl)ethylidenebisphosphonic acid monosodium 

Relevant articles and documents

Optimized synthesis of N-heterocyclic dronic acids; Closing a black-box era

To clarify the inconsistent patent literature, the synthesis of Zoledronic and Risedronic acids involving a heterocyclic acetic acid (HAA), phosphorous acid (PA) and phosphorus trichloride (PC) as the reagents, and methanesulfonic acid as the solvent was studied in detail. It was found that the best synthesis can be accomplished at 80 °C using HAA and PC in a 1:3.1 molar ratio without any PA.

Microwave-assisted efficient synthesis of bisphosphonate libraries: A useful procedure for the preparation of bisphosphonates containing nitrogen and sulfur

Microwave-assisted rapid and efficient procedure for the synthesis of bisphosphonate and their libraries is described in solvent-free medium. Bisphosphonates having nitrogen and sulfur are synthesized following this new procedure. This procedure is simple and can be useful for the generation of compound libraries of a class of bone-resorptive inhibitors such as N- and N-, S- containing bisphosphonates.

Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy

We have investigated the effects in vitro of a series of bisphosphonates on the proliferation of Trypanosoma cruzi, Trypanosoma brucei rhodesiense, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum. The results show that nitrogen-containing bisphosphonates of the type used in bone resorption therapy have significant activity against parasites, with the aromatic species having in some cases nanomolar or low-micromolar IC50 activity values against parasite replication (e.g. o-risedronate, I50 = 220 nM for T. brucei rhodesiense; risedronate, IC50 = 490 nM for T. gondii). In T. cruzi, the nitrogen-containing bisphosphonate risedronate is shown to inhibit sterol biosynthesis at a pre-squalene level, most likely by inhibiting farnesylpyrophosphate synthase. Bisphosphonates therefore appear to have potential in treating parasitic protozoan diseases.